LRRK2 as a target for modulating immune system responses.
Biomarkers
Immune system
Inflammation
Kinase inhibitors
LRRK2
Parkinson's disease
Journal
Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
16
02
2022
revised:
07
04
2022
accepted:
08
04
2022
pubmed:
16
4
2022
medline:
20
5
2022
entrez:
15
4
2022
Statut:
ppublish
Résumé
Mutations in the Leucine-Rich Repeat Kinase 2 (LRRK2) gene are associated with familial and sporadic cases of Parkinson's disease (PD) but are also found in patients with immune- related disorders, such as inflammatory bowel disease (IBD) and leprosy, linking LRRK2 to the immune system. Supporting this genetic evidence, in the last decade LRRK2 was robustly shown to modulate inflammatory responses at both systemic and central nervous system level. In this review, we recapitulate the role of LRRK2 in central and peripheral inflammation in PD and inflammatory disease models. Moreover, we discuss how LRRK2 inhibitors and anti- inflammatory drugs may be beneficial at reducing disease risk/progression in LRRK2-mutation carriers and manifesting PD patients, thus supporting LRRK2 as a promising disease-modifying PD strategy.
Identifiants
pubmed: 35427743
pii: S0969-9961(22)00116-4
doi: 10.1016/j.nbd.2022.105724
pii:
doi:
Substances chimiques
LRRK2 protein, human
EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
EC 2.7.11.1
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105724Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.